Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis.
Medicine (Baltimore)
; 102(48): e36313, 2023 Dec 01.
Article
en En
| MEDLINE
| ID: mdl-38050265
ABSTRACT
BACKGROUND:
This study aimed to investigate the efficacy and safety of baricitinib in patients with severe coronavirus disease 2019 (COVID-19).METHODS:
Databases were searched for studies that compared the clinical efficacy and adverse effects of baricitinib with standard therapy for the treatment of severe COVID-19 and clearly reported relevant outcomes published until December 31, 2022. The corresponding data were extracted from these studies. A fixed-effects model was used to calculate the pooled estimates. The study protocol can be accessed at PROSPERO (CRD42023394173).RESULTS:
The baricitinib group had a significantly lower mortality rate and proportion of patients who received mechanical ventilation than the control group (ORâ =â 0.61, 0.57; Pâ =â .008, 0.02; 95% CI 0.42-0.88; 0.35-0.92; I2â =â 71% and 86%, respectively). The length of hospital stay and rates of severe adverse events were not significantly different between the 2 groups.CONCLUSION:
Baricitinib reduces mortality and mechanical ventilation requirements in patients with severe COVID-19. Therefore, we developed a comprehensive understanding of the role of baricitinib in patients with severe COVID-19.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Azetidinas
/
COVID-19
Tipo de estudio:
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2023
Tipo del documento:
Article
País de afiliación:
China